Abstract
Multidrug resistance (MDR) constitutes the major obstacle to the successful treatment of cancer. In several cancer cells, MDR is thought to be mediated by the super-expression of P-glycoprotein (Pgp). Pgp extrudes drugs from the cells, therefore reducing their cytotoxicity, and its activity inhibition may reverse the MDR phenotype. The present study evaluated the possible cytotoxic effect and MDR reversing properties of the extract and compounds isolated from Phyllanthus amarus . To this purpose, two human leukaemia cell lines were employed: K-562 and its vincristine-resistant counterpart Lucena-1, a Pgp-overexpressing subline. We report here that Lucena-1 was significantly more resistant to the cytotoxicity of P. amarus derivatives: the hexane extract (HE, 100 μg/mL), the lignans-rich fraction (LRF, 100 μg/mL) and the lignans nirtetralin (NIRT, 43.2 μg/mL), niranthin (NIRA, 43 μg/mL) or phyllanthin (PHYLLA, 43 μg/mL) exerted cytotoxic effects on K-562 cells with 40.3, 66.0, 62.0, 61.0 or 24.1 % of cell death, respectively. The cellular toxicity observed on Lucena-1 was 16.3, 40.4, 29.4, 30.2, or 24.8 %, respectively. However, cell treatment with the lignan phyltetralin (PHYLT) up to 41.6 μg/mL had no cytotoxic action on either of the cell lines. P. amarus derivatives were also found to be effective in inhibiting Pgp activity as assessed by rhodamine accumulation in Lucena-1 cells, as were the classical Pgp inhibitors, cyclosporine A (160 nM), PSC-833 (2 μM) and verapamil (5 μM). The lignan NIRT produced the most potent inhibition (EC50 = 29.4 μg/mL) followed by NIRA (44.3 μg/mL), LRF (49.1 μg/mL), PHYLT (99.4 μg/mL), PHYLLA and HE (> 100 μg/mL). Lucena-1 cells were more resistant to daunorubicin-induced cell death (LC50 = 50 μM) than K562 cells (LC50 = 4.95 μM). Of note, the P. amarus derivatives significantly potentiated 5μM daunorubicin-induced cell death in Lucena-1 cells (P < 0.01) but not in K562 cells. After treatment only with P. amarus derivatives (100 μg/mL HE, 30 μg/mL LRF, 12.9 μg/mL NIRA, 43.2 μg/mL NIRT, 43 μg/mL PHYLLA or 41.6 μg/mL PHYLT), the Lucena-1 cellular viability was 83.7, 85.3, 101, 69.7, 75.6 or 88.7 %, respectively, whereas the in the presence of daunorubincin, which was not cytotoxic per se , the cell viability decreased to 42.9, 42.2, 64.2, 35.4, 30.4 or 52.6 %, respectively. Together, these results suggest a potential action of P. amarus derivatives as MDR reversing agents, mainly due to their ability to synergize with the action of conventional chemotherapeutics.
Key words
Phyllanthus amarus
- Euphorbiaceae - lignans - multidrug resistance - P-glycoprotein - human leukaemia cells - cancer
References
in vitro : cross-resistance, radioautographic, and cytogenetic studies.
Cancer Res.
1970;
30
1174-84
Momordica charantia extract.
Cancer Chemother Pharmacol.
2004;
54
525-30
Bupleurum scorzonerifolium
.
Phytochemistry.
2003;
64
1375-9
Ephedra viridis
.
Planta Med.
2005;
71
789-91
Phyllanthus amarus
.
Planta Med.
2005;
71
721-6
Schisandra hernyi with DNA cleaving activity and cytotoxic effect on leukemia and Hela cells in vitro
.
Fitoterapia.
2005;
76
370-3
Phyllanthus : their chemistry, pharmacology, and therapeutic potential.
Med Res Rev.
1998;
18
225-58
Phyllanthus amarus extract administration increases the life span of rats with hepatocellular carcinoma.
J Ethnopharmacol.
2000;
73
215-9
Phyllanthus amarus extract.
J Ethnopharmacol.
2002;
81
17-22
Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.
Eur J Pharmacol.
2003;
478
145-53
in vitro and in vivo
.
J Pharmacol Exp Ther.
1998;
287
963-8
calixto@farmaco.ufsc.br
calixto3@terra.com.br
